Vaccine statement from Minister Koca after the Scientific Committee Meeting
The first Scientific Committee of 2021 convened under the chairmanship of Health Minister Fahrettin Koca. After the meeting, Minister Koca said, 'We discussed the vaccine planning. Our plans are ready. Be sure that we will use all our strength for vaccination, which we hope to end the devastating impact of the global pandemic. Until now, 17 thousand 700 doses of vaccine have been administered to more than 10 thousand volunteers and the results are still being monitored. said.
Following the "Emergency Use Approval", it is aimed to vaccinate all eligible citizens over the age of 18, starting with the elderly and people in critical positions. used expressions.
A STRONG DEAL FOR 50 MILLION DOSE INACTIVE VACCINES AS TODAY
Today, at the first Scientific Board meeting of 2021, we discussed the most critical issue on the agenda, vaccine preparations. I try to inform you regularly about the developments regarding vaccine supply. As of today, we have made a final agreement for 50 million doses of inactive vaccine and received the first part of 3 million doses to our warehouses. In addition, for mRNA-based vaccine, we held a meeting again today and reviewed the new procurement plan. 4.5 million doses of warranty and up to 30 million doses of our agreement have been signed. I will continue to inform you as the details about the procurement plan become clear.
TALKS ARE ALSO CONTINUING FOR VACCINES DEVELOPED IN RUSSIA AND UK
In addition, our negotiations are ongoing for adenovirus-based vaccines developed in Russia and England.
SO HOW MORE THAN 10,000 VOLUNTEERS HAVE BEEN IMPLEMENTED AND THE RESULTS ARE CONTINUING TO BE FOLLOWED
I would like to explain some information about the inactivated vaccine, where we will start the vaccination program first. As you know, the clinical study of this vaccine is ongoing in our country. In order to start the vaccination program, we requested intermediate results from our scientists who carried out the study on the vaccine. According to the interim results, we understood that the vaccine was safe and effective enough and started the process for Emergency Use Approval. Safety tests are ongoing for currently delivered vaccines. As soon as the tests are completed, Emergency Use Approval will be given if the results are suitable. After requesting intermediate results during the clinical trial phase and seeing that the vaccine is safe, our scientists who conducted the research were notified that they would no longer accept new volunteers. Once the vaccine is found to be safe, it is necessary not to continue recruiting new volunteers. Until now, 17,700 doses of vaccine have been administered to over 10,000 volunteers and the results are still being monitored. The country of origin of the inactive vaccine has had Emergency Use Approval for a long time. While giving Emergency Use Approval, the most up-to-date data about the study will be examined.
Our communication with Indonesia, another country where the work continues, continues. Mutual information